Medline (MDLN) Liabilities and Shareholders Equity (2024 - 2026)

Medline (MDLN) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $39.0 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $39.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113.5 billion (changed N/A YoY) and the FY2025 annual result came in at $38.5 billion, up 6.97% from the prior year.
• Liabilities and Shareholders Equity advanced to $39.0 billion in Q1 2026 per MDLN's latest filing, from $38.5 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $39.0 billion in Q1 2026 and bottomed at $36.0 billion in Q4 2024.
• The 3-year median for Liabilities and Shareholders Equity is $38.5 billion (2025), against an average of $37.8 billion.
• Peak annual rise in Liabilities and Shareholders Equity reached 6.97% in 2025, while the deepest fall reached 6.97% in 2025.
• Tracing MDLN's Liabilities and Shareholders Equity over 3 years: stood at $36.0 billion in 2024, then rose by 6.97% to $38.5 billion in 2025, then grew by 1.38% to $39.0 billion in 2026.
• Per Business Quant, the three latest MDLN Liabilities and Shareholders Equity figures stand at $39.0 billion (Q1 2026), $38.5 billion (Q4 2025), and $36.0 billion (Q4 2024).

Peer Comparison